Full Press Release Details
Rockwell Medical Schedules Conference Call
Reporting Fourth Quarter and
WIXOM, MICHIGAN, January 27, 2012 Rockwell Medical (Nasdaq: RMTI), a fully-integrated biopharmaceutical
company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, announced today that it will hold an investor conference
call on Thursday, March 1, 2012 at 8:30 a.m. ET to discuss its fourth quarter and year end 2011 results. Robert Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call. Rockwell will be releasing its earnings results on the
same date. Revenue for 2011 is anticipated to be approximately $49 million and consistent with management expectations.
Internet: http://ir.rockwellmed.com/
Toll-free Dial In: (877) 383-7438
About Rockwell Medical:
Rockwell Medical is a fully-integrated biopharmaceutical company
offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia. The Company is currently developing unique, proprietary renal drugs to treat anemia and secondary
hyperparathyroidism. Rockwell s lead drug candidate for iron therapy treatment is called SFP. SFP delivers iron in a non-invasive, physiologic manner to dialysis patients via dialysate during their regular dialysis treatment. SFP
is currently in ongoing Phase III clinical trials (CRUISE-1 and CRUISE-2) and addresses a $600M U.S. market. Rockwell s Calcitriol (Active Vitamin D) injection for treating secondary hyperparathyroidism is expected to be available
commercially in the second-half of 2012, addressing a $350M U.S. market.
Rockwell is also an established manufacturer and leader in delivering
high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. These products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's
bloodstream. Rockwell s operating business is designed as a ready-made sales and distribution channel to provide seamless integration for its drug products into the commercial markets, Calcitriol in 2012 and SFP upon FDA market
Rockwell s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of
dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for
indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of SFP s unique mechanism of action in delivering iron via dialysate, please view the animation video at
Certain statements in this press release constitute
forward-looking statements within the meaning of the federal securities laws. Words such as may, might, will, should, believe, expect, anticipate,
estimate, continue, predict, forecast, project, plan , intend or similar expressions, or statements regarding intent, belief, or current expectations, are
forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this
release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical s SEC filings. Thus, actual results
could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact: Michael Rice, Investor Relations, 201-408-4923 / 917-282-3242